Treatment of systemic mastocytosis with denileukin diftitox [5]

American Journal of Hematology

Volumn 82, Issue 12, 2007, Pages 1124-

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; DASATINIB; DENILEUKIN DIFTITOX; IMATINIB;

ADULT; AGED; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOPHOSPHATEMIA; LETTER; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; BONE MARROW CELLS; DIPHTHERIA TOXIN; HUMANS; INTERLEUKIN-2; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; RECOMBINANT FUSION PROTEINS;

EID: 36749037723     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21013     Document Type: Letter

References (5)

1. Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006;107:1429-1439.
2. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-1325.
3. William D, Snider CE, Strom TB, et al. Structure/function analysis of interleukin-2-toxin (DAB486IL-2): Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990;265:118-185.
4. Re G, Waters C, Posson L, et al. Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res 1996;56:2590-2595.
5. Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22:4095-4102.